BioNTech is investing US$150 million to establish an mRNA vaccine manufacturing facility in Rwanda, Africa.
The facility aims to produce customised vaccines with specific requirements. The manufacturing capacity depends on the mRNA product being produced, encompassing factors like dosage, formulation, and other pertinent variables.
After validation, the facility will stand as a flagship project for upcoming mRNA-based vaccine manufacturing facilities, catering to varying scales—smaller or larger. These will aid in supporting clinical development or commercial-scale production, tailored to meet local or regional demands effectively.
Additionally, ongoing progress is being made in developing mRNA vaccine candidates for crucial infectious diseases like tuberculosis, malaria, and HIV, as well as for potential pandemic threats such as mpox. Upon successful development and regulatory approval, these vaccines are slated for production at the recently established site.
Completion of all buildings at the Kigali site and the initiation of local training for specialised personnel within the facility are scheduled for 2024. Additionally, it aims to begin test mRNA production for process validation in 2025.
Type New Construction
Budget US$150 million